GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProQR Therapeutics NV (FRA:0PQ) » Definitions » Cyclically Adjusted PB Ratio

ProQR Therapeutics NV (FRA:0PQ) Cyclically Adjusted PB Ratio : 0.63 (As of Sep. 21, 2024)


View and export this data going back to 2014. Start your Free Trial

What is ProQR Therapeutics NV Cyclically Adjusted PB Ratio?

As of today (2024-09-21), ProQR Therapeutics NV's current share price is €1.554. ProQR Therapeutics NV's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 was €2.48. ProQR Therapeutics NV's Cyclically Adjusted PB Ratio for today is 0.63.

The historical rank and industry rank for ProQR Therapeutics NV's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:0PQ' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.42   Med: 0.68   Max: 0.92
Current: 0.65

During the past years, ProQR Therapeutics NV's highest Cyclically Adjusted PB Ratio was 0.92. The lowest was 0.42. And the median was 0.68.

FRA:0PQ's Cyclically Adjusted PB Ratio is ranked better than
68.81% of 606 companies
in the Biotechnology industry
Industry Median: 1.605 vs FRA:0PQ: 0.65

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

ProQR Therapeutics NV's adjusted book value per share data for the three months ended in Jun. 2024 was €0.402. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €2.48 for the trailing ten years ended in Jun. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


ProQR Therapeutics NV Cyclically Adjusted PB Ratio Historical Data

The historical data trend for ProQR Therapeutics NV's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProQR Therapeutics NV Cyclically Adjusted PB Ratio Chart

ProQR Therapeutics NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.71

ProQR Therapeutics NV Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.58 0.47 0.71 0.83 0.61

Competitive Comparison of ProQR Therapeutics NV's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, ProQR Therapeutics NV's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProQR Therapeutics NV's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where ProQR Therapeutics NV's Cyclically Adjusted PB Ratio falls into.



ProQR Therapeutics NV Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

ProQR Therapeutics NV's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.554/2.48
=0.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProQR Therapeutics NV's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, ProQR Therapeutics NV's adjusted Book Value per Share data for the three months ended in Jun. 2024 was:

Adj_Book=Book Value per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=0.402/129.9100*129.9100
=0.402

Current CPI (Jun. 2024) = 129.9100.

ProQR Therapeutics NV Quarterly Data

Book Value per Share CPI Adj_Book
201409 4.765 99.960 6.193
201412 4.688 99.050 6.149
201503 4.709 99.750 6.133
201506 4.354 100.230 5.643
201509 4.096 100.500 5.295
201512 3.846 99.730 5.010
201603 3.435 100.310 4.449
201606 3.038 100.260 3.936
201609 2.631 100.570 3.399
201612 2.276 100.710 2.936
201703 1.916 101.440 2.454
201706 1.526 101.370 1.956
201709 1.286 102.030 1.637
201712 1.233 101.970 1.571
201803 0.926 102.470 1.174
201806 0.716 103.100 0.902
201809 2.649 103.950 3.311
201812 2.390 103.970 2.986
201903 2.086 105.370 2.572
201906 1.815 105.840 2.228
201909 1.539 106.700 1.874
201912 1.896 106.800 2.306
202003 1.638 106.850 1.992
202006 1.597 107.510 1.930
202009 1.369 107.880 1.649
202012 1.137 107.850 1.370
202103 0.974 108.870 1.162
202106 1.761 109.670 2.086
202109 1.807 110.790 2.119
202112 1.597 114.010 1.820
202203 1.413 119.460 1.537
202206 1.224 119.050 1.336
202209 0.909 126.890 0.931
202212 0.830 124.940 0.863
202303 0.729 124.720 0.759
202306 0.640 125.830 0.661
202309 0.571 127.160 0.583
202312 0.509 126.450 0.523
202403 0.426 128.580 0.430
202406 0.402 129.910 0.402

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ProQR Therapeutics NV  (FRA:0PQ) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


ProQR Therapeutics NV Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of ProQR Therapeutics NV's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ProQR Therapeutics NV Business Description

Traded in Other Exchanges
Address
Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.

ProQR Therapeutics NV Headlines

No Headlines